Resmed Inc [RMD] stock prices are down -0.12% to $245.49 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RMD shares have lost -1.24% over the last week, with a monthly amount glided 14.48%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Resmed Inc [NYSE: RMD] stock has seen the most recent analyst activity on March 19, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $280. On January 16, 2025, Goldman initiated with a Buy rating. Piper Sandler started tracking the stock assigning a Neutral rating and suggested a price target of $252 on January 10, 2025. Stifel initiated its recommendation with a Hold and recommended $250 as its price target on December 13, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 24, 2024, and assigned it a price target of $280. In a note dated September 18, 2024, Wolfe Research downgraded an Underperform rating on this stock but restated the target price of $180.
The stock price of Resmed Inc [RMD] has been fluctuating between $179.42 and $263.05 over the past year. Currently, Wall Street analysts expect the stock to reach $259.75 within the next 12 months. Resmed Inc [NYSE: RMD] shares were valued at $245.49 at the most recent close of the market. An investor can expect a potential return of 5.81% based on the average RMD price forecast.
Analyzing the RMD fundamentals
The Resmed Inc [NYSE:RMD] reported sales of 5.02B for trailing twelve months, representing a surge of 7.92%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.32%, Pretax Profit Margin comes in at 0.31%, and Net Profit Margin reading is 0.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.17, Equity is 0.25 and Total Capital is 0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Resmed Inc [NYSE:RMD]’s Current Ratio is 3.41. As well, the Quick Ratio is 2.49, while the Cash Ratio is 0.99. Considering the valuation of this stock, the price to sales ratio is 7.17, the price to book ratio is 6.50 and price to earnings (TTM) ratio is 27.56.
Transactions by insiders
Recent insider trading involved Sandercock Brett, Officer, that happened on May 22 ’25 when 3644.0 shares were purchased. Director, De Witte Jan completed a deal on May 20 ’25 to sell 2000.0 shares. Meanwhile, Director De Witte Jan bought 2000.0 shares on May 20 ’25.
